

TULIP MULTISPECIALITY HOSPITAL PRIVATE LIMITED

Regd Office: W- 4, 2nd Floor, Green Park, South West Delhi, New Delhi - 110016

CIN: U93000DL2013PTC248689

Email: tulipaaadgroup@gmail.com; Website: www.tuliphospital.com

Contact No: + 91 8607007979

DIRECTORS' REPORT

To,

The Shareholders

Tulip Multispeciality Hospital Private Limited,

W- 4, 2nd Floor, Green Park, South West Delhi,

New Delhi, India- 110016

Yours Directors are pleased to present before you the Fourteenth (14th) Annual report on the business and operations of the Company together with the Audited Statement and the Auditor's report of your Company for the Financial Year ended 31st March 2026.

1. FINANCIAL SUMMARY & PERFORMANCE OF THE COMPANY:

The financial results of the Company for the Financial Year ended on March 31, 2026 are as follows:

(Amount in thousand)

PARTICULARS	For the Financial Year ended March 31, 2026 (Amount in INR thousand)	For the Financial Year ended March 31, 2025 (Amount in INR thousand)
Revenue from operations	5,75,938.55	5,76,173.05
Other Income	2,486.64	1,627.47
Total Income	5,78,425.20	5,77,800.52
Finance Cost	3,294.37	3,831.46
Depreciation/Amortisation/ Impairment	31,365.21	33,909.91
Employee Benefit Cost	85,097.21	82,895.49
Amortization expenses	-	-
Other Expenses	3,32,405.83	3,21,881.05
Total Expenses	5,39,607.04	5,26,563.47
Profit/ Loss before Exceptional Items & Tax	38,818.16	51,237.04
Profit (Loss) before Tax	38,818.16	51,237.04
Less: Provision for Tax		
Current	10,558.81	14,995.14
Deferred	285.31	(487.99)
Net Profit/Loss for the Year	27,974.04	36,729.89



2. STATE OF COMPANY'S AFFAIRS:

(Amount in thousand)

During the current Financial Year, the Company has received total revenue of INR 5,78,425.20 as compared to INR 5,77,800.52/- in previous Financial Year. Further, your Company has earned a profit of INR 27,974.04 in the current Financial Year as compared to profit earned of INR 36,729.89/- in the previous Financial Year.

During the Financial Year 2025-26, your Company has managed the affairs in a fair and transparent manner, and there was no change in the business of the Company.

3. TRANSFER TO RESERVES

During the year under review, no amount has been transferred to General Reserves.

4. DIVIDEND

During the year under review, Directors do not recommend any dividend.

5. SHARE CAPITAL

The Authorized Share Capital of the Company as on March 31, 2026 was INR 25,00,000/- (Indian Rupees Twenty-Five Lakh Only) comprising of 2,50,000 (Two Lakh Fifty Thousand) Equity Shares of INR 10/- (Indian Rupees Ten Only) each.

The issued, subscribed and Paid up Share Capital of the Company as on March 31, 2026 was INR 13,00,000/- (Indian Rupees Thirteen Lakh Only) comprising of 1,30,000 (One Lakh Thirty Thousand) Equity Shares of INR 10/- (Indian Rupees Ten Only) each.

There has been no change in the share capital of the Company during the Financial Year ended March 31, 2026.

6. ANNUAL RETURN

In compliance with the provisions of Section 92(3) read with Section 134(3) (a) of the Act, the Annual return of the Company as on March 31, 2026, can be accessed at: www.tuliphospital.com

7. HOLDING, SUBSIDIARY COMPANY(S)/ASSOCIATE/JOINT VENTURE

The Company does not have any Holding Company, Subsidiary Company, Associate or Joint Venture Company as defined under the Companies Act, 2013 during the Financial Year ended on March 31, 2026 and there was no change in this position during the Financial Year 2025-26.



8. KEY MANAGERIAL PERSONNEL

During the year under review, the Company was not required to appoint Key Managerial Personnel(s).

9. NUMBER OF MEETINGS OF THE BOARD

The Board meets at regular intervals to discuss and decide on Company / business policy and strategy apart from other Board business. The Notice, Agenda and Notes on agenda duly circulated to Board of Directors in order to facilitate them to plan their schedule.

During the Financial Year 2025-26, the Board of Directors duly met Thirteen (13) times.

The intervening gap between the board meetings did not exceed 120 days, as prescribed under the Companies Act, 2013.

10. PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS UNDER SECTION 186

Pursuant to the provisions of Section 186 of the Act read with Rule 11(2) of the Companies (Meetings of Board and its Powers) Rules, 2014, the Company has not made any loan, given any guarantee or provided any security during the period under review.

11. RELATED PARTY TRANSACTIONS

Particulars of contracts or arrangements with related parties referred to in Section 188(1) of the Companies Act, 2013, in the prescribed Form AOC-2, is appended as **Annexure- I** to the Board's Report.

12. STATUTORY AUDITOR & AUDIT REPORT

Pursuant to the provisions of Section 139 and all other applicable provisions of the Companies Act, 2013 read with the Companies (Audit and Auditors), Rules, 2014, M/s R. K. Khurana & Associates, Chartered Accountants, having registration No. 006017N, was appointed as the Statutory Auditors of the Company to hold the office for a period of 5 (five) years at the 9th Annual General Meeting upto the conclusion of the 14th Annual General Meeting of the Company to be held for financial year 2025-26. The Statutory Auditors have confirmed that they are not disqualified to continue as Statutory Auditors and are eligible to hold office as Statutory Auditors of your Company.

13. AUDITORS' REPORT



The Statutory Audit Report for the Financial Year ended on March 31, 2026 does not contain any qualification, reservation or adverse remark or disclaimer made by Statutory Auditors.

14. REPORTING OF FRAUDS BY AUDITORS

As per Section 134(3)(ca) during the year under review, there were no frauds reported by the Auditors to the Board under Section 143(12) of the Act.

15. SIGNIFICANT REGULATORY OR COURT OR TRIBUNAL ORDERS

Following are the list of relevant litigations by/against the Company:

- (1) During the Financial Year 2021-2022, Saxena Multispeciality Hospital Private Limited (holding 3.85% of Paid-up share capital) along with Dr. Akhil Saxena and Dr. Divya Saxena (both ex-directors of the Company and promoters of Saxena Multispeciality Hospital Private Limited), had filed a Company Petition 217/ND/2021 before the National Company Law Tribunal, New Delhi ('NCLT') under Section 241, 242 of Companies Act, 2013 in relation to alleged oppression and mismanagement of the affairs of the Company.. The said Petition was allowed by the Hon'ble NCLT vide Order dated 10 April 2026, inter alia, declaring the Rights Issue dated 28 July 2020 and consequential allotment of 1,20,000 equity shares as null and void and directing rectification of the Register of Members. The Hon'ble NCLT also directed appointment of an Administrator on the Board for a period of 90 days.

Aggrieved by the said Order, the Company and Others preferred Company Appeal (AT) No. 129 of 2026 before the Hon'ble National Company Law Appellate Tribunal (NCLAT), New Delhi. Vide Order dated 13 April 2026, the directions relating to appointment of the Administrator were kept in abeyance and the same continue to remain in force. Further, on the hearing held on 7 May 2026, the Respondents undertook before the Hon'ble NCLAT not to initiate any proceedings, including contempt proceedings, for execution of the directions contained in the Order dated 10 April 2026.

The Appeal is presently at the stage of hearing of arguments and is next listed for hearing on 7 October 2026.

- (2) The Company had filed a complaint case under Section 452 of the Companies Act, 2013, read with Section 200 of the Code of Criminal Procedure, against Dr. Akhil Saxena and Dr. Divya Saxena, former directors of the Company, alleging unlawful retention and misappropriation of certain machines and other assets belonging to the Company. The complaint was dismissed by the Learned ACMM, Tis Hazari Courts, Delhi, vide order dated 6 February 2023. The Company thereafter preferred Criminal Revision Petition No. 245/2023 before the Hon'ble High Court of Delhi. The said Revision Petition was allowed by the Hon'ble High Court vide judgment dated 5 January 2026, whereby the Order dated 6 February 2023 was set aside and the complaint case was revived and remanded to the Learned Additional Chief Judicial Magistrate (Special Acts), Central, Tis Hazari Courts, Delhi, for further proceedings.



The matter is presently at the stage of framing of notice against the accused and is next listed for hearing on 26 September 2026.

Other ongoing litigations are related to commercial matters and has no significant impact on going concern status of the Company.

16. TRANSFER TO INVESTOR EDUCATION AND PROTECTION FUND

The Company was not required to transfer any funds to Investor Education and Protection Fund during the Financial Year ended March 31, 2026.

17. MAINTENANCE OF COST RECORDS

Maintenance of cost records as specified under sub-section (1) of section 148 of the Companies Act, 2013, is not required by the Company and accordingly such accounts and records are not required to be made and maintained.

18. MATERIAL CHANGES AND COMMITMENTS

No material changes except as mentioned in this Report and commitments affecting the Financial Position of the Company have occurred from the end of the Financial Year of the Company as at March 31, 2026 till the date of signing of this Report.

19. DETAILS OF APPLICATION MADE OR ANY PROCEEDING PENDING UNDER THE INSOLVENCY AND BANKRUPTCY CODE, 2016 (31 OF 2016) DURING THE YEAR ALONGWITH THEIR STATUS AS AT THE END OF THE FINANCIAL YEAR

No application has been made or proceeding are pending under the Insolvency and Bankruptcy Code, 2016 (31 of 2016) during the year under review.

20. THE DETAILS OF DIFFERENCE BETWEEN AMOUNT OF THE VALUATION DONE AT THE TIME OF ONE TIME SETTLEMENT AND THE VALUATION DONE WHILE TAKING LOAN FROM THE BANKS OR FINANCIAL INSTITUTIONS ALONG WITH THE REASONS THEREOF

The above statement does not applicable on the Company during the period under review.

21. COMPLIANCE WITH MATERNITY BENEFIT ACT 1961

During the period under review, the Company has complied with the provisions of the Maternity Benefit Act 1961 for eligible female employees. The Company has also implemented a policy to encourage female employees to avail themselves of the maternity leave benefits.

The Company has duly implemented a policy on Maternity Benefit Act in compliance with the provisions of Maternity Benefit Act, 1961 and amendment thereof.



22. STATEMENT ON DECLARATION GIVEN BY INDEPENDENT DIRECTORS UNDER SUB-SECTION (6) OF SECTION 149

During the period under review, since Company is a Private Limited Company, the requirement prescribed under section 149(6) of the Companies Act 2013 is not applicable.

23. PARTICULARS OF EMPLOYEES PURSUANT TO SECTION 197

The provisions of Section 197 of the Companies Act 2013, read along with the Companies (Appointment and Remuneration of Managerial Personnel) Rules 2014 are not applicable to Private Companies.

24. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNINGS AND OUTGO

The information on conservation of energy, technology absorption and foreign exchange earnings & outgo as stipulated under Section 134(3)(m) of the Act read with Companies (Accounts) Rules, 2014 is as follows:

a) Conservation of Energy

(i) The steps taken or impact on conservation of energy

Regular efforts are made to conserve the energy through various means such as use of low energy consuming lightings, etc.

(ii) The steps taken by the Company for using alternate sources of energy

Since your Company is not an energy intensive unit, utilization of alternate source of energy may not be feasible.

(iii) Capital investment on energy conservation equipment: Nil

b) Technology Absorption

Your Company is not engaged in Service activities therefore, there is no specific Information to be furnished in this regard.

There was no expenditure on research and development during the period under review.

c) Foreign Exchange Earnings and Outgo

There were no foreign exchange earnings and outgo during the Financial Year ended March 31, 2026.

25. DIRECTORS

During the year under review, there were no changes in the directorship of the Board of Directors. Further, as on March 31, 2026, following were the Directors of the Company:

- 1) Dr. Anurag Arora; and
- 2) Dr. Anupama Sethi.



26. PUBLIC DEPOSITS

During the year under review, the Company has neither invited nor accepted any deposits from the public within the meaning of Section 73 of the Companies Act, 2013 and, as such, no amount on account of principal or interest on public deposits was outstanding as on the date of the Balance Sheet.

27. CORPORATE SOCIAL RESPONSIBILITY

The Company has duly formulated CSR Policy indicating the activities to be undertaken by the Company, in pursuance to Section 135 (1) of the Companies Act 2013 read with the Companies (Corporate Social Responsibilities Policy) Rules, 2014.

As per sub-section 135(9), where the amount to be spent by a Company under 135 (5) does not exceed fifty lakh rupees, the requirement under 135(1) in relation to constitution of the Corporate Social Responsibility (CSR) Committee is not applicable and the functions of such Committee as provided under section 135 shall be discharged by the Board of Director Thus, the functions of the CSR Committee are discharged by the Board of Director.

Further, being a profit-making Company, the Company was required to spend 2% of average net profit of previous three Financial Years towards CSR. In furtherance of the same, the contribution to 'PM Care Fund', 'Snehkar Foundation' towards Charity for Education and 'Society for Action in Community Health- SACH' towards the act of Distribution of Malnutrition kit to kids, was made by the Company.

Further, in terms of Rule 8 of the Companies (Corporate Social Responsibility Policy) Rules, 2014, the Annual Report on CSR is annexed herewith the report as **Annexure-II**.

28. DISCLOSURE AS PER THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013

The Company has zero tolerance towards sexual harassment at the workplace and has adopted a policy on prevention, prohibition and redressal of sexual harassment at workplace in line with the provisions of the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 and the Rules thereunder.

The Company has duly constituted the Internal Complaint Committee in terms of Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 which oversee and redress the complaints, if any, of the employees of the Company as well.



Your Directors further state that during the year under review, no complaints have been received by the Company pursuant to the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013.

29. DIRECTORS' RESPONSIBILITY STATEMENT U/S SECTION 134

Pursuant to the requirement under section 134(3)(c) of the Companies Act, 2013 with respect to Directors' Responsibility Statement, it is hereby confirmed that:

- a. In the preparation of the annual accounts for the Financial Year ended 31st March, 2026, the applicable accounting standards had been followed along with proper explanation relating to material departures;
- b. the Directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company as at 31st March, 2026 and of the profit and loss of the company for that period;
- c. the Directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 2013 for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;
- d. the Directors had prepared the annual accounts on a going concern basis; and
- e. the Directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

30. INTERNAL FINANCIAL CONTROLS

The Company has in place adequate internal financial controls with reference to financial statements. The internal financial control with respect to the Financial Statement are adequate in the opinion of the Board of Directors of the Company.

Also, the Company has a proper system of internal control to ensure all the assets are safeguarded and protected against loss from unauthorized use or disposition and that transaction are authorized, recorded and reported correctly.

During the year, such controls were tested and no reportable material weaknesses in the design or operation effectiveness were observed. In the opinion of the Board, the existing internal control framework is adequate and commensurate with the size and nature of the business of the Company.



31. DISCLOSURE OF COMPOSITION OF AUDIT COMMITTEE AND PROVIDING VIGIL MECHANISM

The provisions of Section 177 of the Companies Act, 2013 read with rule 6 and 7 of the Companies (Meetings of the Board and its Powers) Rules, 2014 is not applicable to the Company.

32. RISK MANAGEMENT

Your Company considers that risk is an integral part of its business and therefore, it takes proper steps to manage all risks in a proactive and efficient manner. The Company management periodically assesses risks in the internal and external environment and incorporates suitable risk treatment processes in its strategy, business and operating plans. There are no risks which, in the opinion of the Board, threaten the very existence of your Company.

33. SECRETARIAL STANDARDS

During the year under review, the Company has complied with the applicable Secretarial Standards on Board Meeting (SS-1) and Secretarial Standards on General Meeting (SS-2) issued by the Institute of Company Secretaries of India ('ICSI') as may be amended time to time.

34. ACKNOWLEDGMENTS

Your Directors take this opportunity to place on record their appreciation and sincere gratitude to the Government and the Bankers to the Company for their valuable support and look forward to their continued co-operation in the years to come.

Your Directors acknowledge the support and co-operation received from the employees and all those who have helped in the day to day management.

Lastly, the Directors are deeply grateful for the confidence and faith shown by the members of the Company in the management.

Date: 02.09.2026

Place: New Delhi

Registered office: W- 4, 2nd Floor,
Green Park, South West Delhi,
New Delhi, India- 110016
CIN: U93000DL2013PTC248689
Email: tulipaaadgroup@gmail.com

**For and on behalf of the Board of Directors
Tulip Multispeciality Hospital Private Limited**

For Tulip Multispeciality Hospital Pvt. Ltd.

Anupama Sethi Director
DIN: 06470073

For Tulip Multispeciality Hospital Pvt. Ltd.

Anurag Arora Director
DIN: 06470060

Annexure- I

Form No. AOC-2

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014)

Form for disclosure of particulars of contracts/arrangements entered into by the Company with related parties referred to in sub-section (1) of section 188 of the Companies Act, 2013 including certain arm's length transactions under third proviso thereto.

I. Details of contracts and arrangements or transactions not at arm's length – NOT APPLICABLE

II. Details of material contracts and arrangements or transactions at arm's length: Number of material contracts or arrangements or transactions at arm's length basis – 11

Corporate identity number (CIN) or any other registration number or PAN/ Passport for individuals	Name(s) of Related Party	Nature of Relationship	Nature of contracts / arrangements / transactions	Duration of the contracts / arrangements / transactions	Salient terms of the contracts or arrangements or transactions including actual / expected contractual amount	Date(s) of approval by the Board, if any	Amount paid as advances , if any
ABQPA9050M	Anupama Sethi	Director, KMP	Professional Fees	NA	As per Agreement	21/02/2013	NIL
ABQPA9050M	Anupama Sethi	Director, KMP	Building Rent	5 years	As per Agreement	24/07/2025	NIL
ABVPA5569Q	Anurag Arora	Director, KMP	Professional Fees	NA	As per Agreement	21/02/2013	NIL
ABVPA5569Q	Anurag Arora	Director, KMP	Building Rent	5 years	As per Agreement	24/07/2025	NIL
ABVPA5569Q	Anurag Arora	Director, KMP	Reimbursement of	NA	As per Agreement	21/02/2013	NIL



			Earnest Money Deposit				
AAZPA6471P	K.L Arora	Relative of KMP	Salary Expense	NA	-	01.06.2019	NIL
CKEPA0531Q	Pulkit Arora	Relative of KMP	Professional Fees	NA	As per Agreement	21/02/2013	NIL
ABHFA9930D	A D Pharma	Enterprise in which Directors having Substantial Interest	Purchase of Medicine	As per MOU	As per MOU	31/08/2016	NIL
AAATL7264M	Life Line Charitable Trust	Enterprise in which Directors having Substantial Interest	Advances on expenses	As per MOU	As per MOU	02/04/2019	NIL
AAETT3472D	Tulip Multispeciality Hospital Employees Gratuity Trust	Enterprise in which Directors having Substantial Control	Contribution to Gratuity Fund	As per Agreement	As per Agreement	10/05/2022	NIL
U86905HR2023 PTC112182	Cube Diagnostics Private Limited	Company in which Directors are having substantial control and are also Directors	Professional Fees	As per Agreement	As per Agreement	20/05/2024	NIL

Date: 02.09.2026

Place: New Delhi

Registered office: W- 4, 2nd Floor,
Green Park, South West Delhi,
New Delhi, India- 110016

CIN: U93000DL2013PTC248689

Email: tulipaaadgroup@gmail.com

For and on behalf of the Board of Directors

Tulip Multispeciality Hospital Private Limited

For Tulip Multispeciality Hospital Pvt. Ltd. For Tulip Multispeciality Hospital Pvt. Ltd.


Director

Anupama Sethi
Director


Director

Anurag Arora
Director

Annexure- II

ANNUAL REPORT ON CSR ACTIVITIES**1. A brief outline on the CSR policy of the Company:**

This policy encompasses the Company's philosophy for giving back to society as a corporate citizen and lays down the guidelines and mechanism for undertaking socially useful programmes for the welfare & sustainable development of the community at large.

This policy shall apply to all CSR initiatives and activities taken up at the various work centers for the benefit of the society.

Purpose

- i) To lay down guidelines to make CSR a key business process for sustainable development of the society. Ensuring the implementation of CSR initiatives in letter and spirit through appropriate procedures and reporting.
- ii) To directly/indirectly undertake projects/programs which will enhance the quality of life and economic well-being of the communities in and around our facilities across the country and society at large.
- iii) Establishing a guideline for compliance with the provisions of Act to dedicate a percentage of the Company's profits for social projects.
- iv) To generate goodwill and recognition among all stakeholders of the Company.

2. Composition of CSR committee:

Not Applicable

3. Provide the web-link(s) where Composition of CSR Committee, CSR Policy and CSR Projects approved by the board are disclosed on the website of the company: www.tuliphospital.com**4. Provide the details of Impact assessment of CSR projects carried out in pursuance of sub-rule (3) of rule 8 of the Companies (Corporate Social responsibility Policy) Rules, 2014: Not Applicable****5. (a) Average net profit of the company as per sub-section (5) of section 135**

2022-23	2023-24	2024-25
7,12,22,820/-	5,33,31,020	5,12,37,040

(b) Two percent of average net profit of the company as per sub-section (5) of section 135

Average Net Profit: 11,71,939

(c) Surplus arising out of the CSR Projects or programmes or activities of the previous Financial Years: NIL

(d) Amount required being set-off for the Financial Year, if any: 3,902.33

(e) Total CSR obligation for the Financial Year [(b)+(c)-(d)]: 11,68,036.67

6. (a) Amount spent on CSR Projects (both Ongoing Project and other than Ongoing Project): NIL

(b) Amount spent in Administrative Overheads: NIL

(c) Amount spent on Impact Assessment, if applicable: Not Applicable

(d) Total amount spent for the Financial Year [(a)+(b)+(c)]: NIL

(e) CSR amount spent or unspent for the Financial Year:

Total Amount Spent for the Financial Year (in INR)	Amount Unspent (in INR)				
	Total Amount transferred to Unspent CSR Account as per section 135(6)		Amount transferred to any fund specified under Schedule VII as per second proviso to section 135(5)		
	Amount	Date of transfer	Name of the Fund	Amount	Date of transfer
12,00,000	NA	NA	NA	NA	NA

(f) Excess amount for set-off, if any

Sl. No.	Particular	Amount (in INR)
(1)	(2)	(3)



(i)	Two percent of average net profit of the company as per sub-section (5) of section 135	11,71,939
(ii)	Total amount spent for the Financial Year	12,00,000
(iii)	Excess amount spent for the Financial Year [(ii)-(i)]	28,061
(iv)	Surplus arising out of the CSR projects or programmes or activities of the previous Financial Years, if any	NIL
(v)	Amount available for set off in succeeding Financial Years [(iii)-(iv)]	28,061

7. **Details of Unspent Corporate Social Responsibility amount for the preceding three Financial Years:** Not Applicable

Sl. No.	Preceding Financial Year.	Amount transferred to Unspent CSR Account under section 135 (6) (in INR)	Amount spent in the reporting Financial Year (in INR).	Amount transferred to any fund specified under Schedule VII as per section 135(6), if any.			Amount remaining to be spent in succeeding financial year (in INR)
				Name of the Fund	Amount (in Rs)	Date of transfer	
1.							
	TOTAL						

8. **Whether any capital assets have been created or acquired through Corporate Social Responsibility amount spent in the Financial Year:** No

9. **Specify the reason(s), if the company has failed to spend two per cent of the average net profit as per section 135(5):** Not Applicable

Date: 02.09.2026

Place: New Delhi

Registered office: W- 4, 2nd Floor,
Green Park, South West Delhi,
New Delhi, India, 110016
CIN: U93000DL2013PTC248689
Email: tulipaaadgroup@gmail.com

For and on behalf of the Board of Directors
Tulip Multispecialty Hospital Private Limited
For Tulip Multispecialty Hospital Pvt. Ltd. For Tulip Multispecialty Hospital Pvt. Ltd.


Anupama Sethi
Director
DIN: 06470073


Anurag Arora
Director
DIN: 06470060

